HK1114567A1 - Airway administration of tissue factor pathway inhibitor in inflammatory conditions affecting the respiratory tract - Google Patents

Airway administration of tissue factor pathway inhibitor in inflammatory conditions affecting the respiratory tract

Info

Publication number
HK1114567A1
HK1114567A1 HK08110145.5A HK08110145A HK1114567A1 HK 1114567 A1 HK1114567 A1 HK 1114567A1 HK 08110145 A HK08110145 A HK 08110145A HK 1114567 A1 HK1114567 A1 HK 1114567A1
Authority
HK
Hong Kong
Prior art keywords
respiratory tract
tissue factor
inflammatory conditions
pathway inhibitor
conditions affecting
Prior art date
Application number
HK08110145.5A
Other languages
English (en)
Inventor
Lars Otto Uttenthal
Original Assignee
Drugrecure Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Drugrecure Aps filed Critical Drugrecure Aps
Publication of HK1114567A1 publication Critical patent/HK1114567A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
HK08110145.5A 2005-06-24 2008-09-11 Airway administration of tissue factor pathway inhibitor in inflammatory conditions affecting the respiratory tract HK1114567A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69396805P 2005-06-24 2005-06-24
PCT/IB2006/002602 WO2006136962A2 (fr) 2005-06-24 2006-06-23 Administration par voies aeriennes de l'inhibiteur de la voie du facteur tissulaire dans des conditions inflammatoires affectant les voies respiratoires

Publications (1)

Publication Number Publication Date
HK1114567A1 true HK1114567A1 (en) 2008-11-07

Family

ID=37570814

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08110145.5A HK1114567A1 (en) 2005-06-24 2008-09-11 Airway administration of tissue factor pathway inhibitor in inflammatory conditions affecting the respiratory tract

Country Status (15)

Country Link
US (3) US8088728B2 (fr)
EP (3) EP1896059B1 (fr)
JP (3) JP2008543925A (fr)
KR (2) KR20080074085A (fr)
CN (2) CN101262879B (fr)
AU (2) AU2006260599A1 (fr)
BR (2) BRPI0613137A2 (fr)
CA (2) CA2612597C (fr)
DK (3) DK1898945T3 (fr)
HK (1) HK1114567A1 (fr)
IL (2) IL188220A0 (fr)
NO (2) NO20080433L (fr)
RU (2) RU2496515C2 (fr)
WO (3) WO2006136962A2 (fr)
ZA (2) ZA200800251B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2101787B1 (fr) * 2006-12-11 2013-09-18 Drugrecure ApS Procédés de traitement de la mucoviscidose ou de la pneumonie avec infection bactérienne par administration pulmonaire de fosfomycine
RU2662564C2 (ru) 2012-07-04 2018-07-26 ЗЗ Байотек ЛЛС Лечение воспалительных заболеваний кожи
AU2014391082B2 (en) * 2014-04-16 2020-04-09 Zz Biotech Llc Treatment of abnormal cutaneous scarring
CA3036553A1 (fr) * 2016-09-13 2018-03-22 Prothera Biologics, Inc. Procedes de traitement d'une maladie pulmonaire a l'aide de proteines inhibitrices d'inter-alpha

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
GR860984B (en) * 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5106833A (en) * 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
US4966852A (en) * 1987-07-23 1990-10-30 Monsanto Company DNA clone of human tissue factor inhibitor
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
US6013619A (en) * 1988-01-06 2000-01-11 The Scripps Research Institute Pulmonary surfactants and therapeutic uses, including pulmonary lavage
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
DK408089D0 (da) * 1989-08-18 1989-08-18 Novo Nordisk As Proteiner
US5378614A (en) * 1989-08-18 1995-01-03 Novo Nordisk A/S Vector and method for making tissue factor pathway inhibitor (TFPI) analogues in yeast
SE9200541D0 (sv) * 1992-02-24 1992-02-24 Kabi Pharmacia Ab New usee of omega-3-fatty acids
US5212091A (en) * 1992-03-02 1993-05-18 Monsanto Company Method of producing tissue factor pathway inhibitor
AU730133B2 (en) * 1996-11-08 2001-02-22 Oklahoma Medical Research Foundation Modified protein C and methods of use thereof
CA2278823A1 (fr) * 1997-01-29 1998-07-30 Joe M. Mccord Activateur du plasminogene utilise comme agent anti-inflammatoire
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6049577A (en) * 1998-05-28 2000-04-11 Glenayre Electronics, Inc. Header synchronization detector
AR023819A1 (es) * 1999-05-03 2002-09-04 Astrazeneca Ab FORMULACIoN FARMACEUTICA, KIT DE PARTES Y UTILIZACION DE DICHA FORMULACION
JP4848092B2 (ja) * 2000-02-01 2011-12-28 石原産業株式会社 ジアミノトリフルオロメチルピリジン誘導体を含有する肺不全の治療剤又は予防剤
ES2234807T3 (es) * 2000-02-02 2005-07-01 Eli Lilly And Company Derivados de proteina c.
ATE428445T1 (de) * 2000-02-11 2009-05-15 Bayer Healthcare Llc Gerinnungsfaktor vii oder viia konjugate
US6933367B2 (en) * 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
EP1385535A2 (fr) * 2001-05-02 2004-02-04 Novo Nordisk A/S Facteur vii modifie pour le traitement du syndrome de detresse respiratoire aigue
DE10132307A1 (de) * 2001-07-06 2003-01-30 Aventis Behring Gmbh Arzneizubereitung zur Inhalation von Antithrombin bei entzündlichen Lungenerkrankungen und ARDS
IL161407A0 (en) * 2001-10-15 2004-09-27 Chiron Corp Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi)
US7189289B2 (en) * 2002-02-08 2007-03-13 Sk Corporation Cleaning agent and method for cleaning heater tubes
NZ536796A (en) * 2002-04-25 2007-03-30 Scripps Research Inst Treatment and prevention of pulmonary conditions comprising at least one lung surfactant polypeptide and at least one protease inhibitor, lipase inhibitor or an anti-oxidant
WO2004062689A1 (fr) * 2003-01-08 2004-07-29 Chiron Corporation Compositions aqueuses stabilisees de tfpi ou de ses variantes
JPWO2004087148A1 (ja) * 2003-03-31 2006-06-29 協和醗酵工業株式会社 肺疾患の治療および／または予防剤
WO2005042011A1 (fr) * 2003-11-04 2005-05-12 Novo Nordisk A/S Composition pharmaceutique contenant un polypeptide de proteine c et un regulateur de glucose sanguin
US8431535B2 (en) * 2004-09-10 2013-04-30 Hoiberg A/S Methods for treating local tracheal, bronchial or alveolar bleeding or hemoptysis
US8563511B2 (en) 2004-10-06 2013-10-22 University Of Rochester Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway

Also Published As

Publication number Publication date
KR20080071116A (ko) 2008-08-01
US8088728B2 (en) 2012-01-03
WO2007012976A3 (fr) 2007-07-12
CN101262879B (zh) 2013-04-10
EP1906994A2 (fr) 2008-04-09
JP2008543925A (ja) 2008-12-04
CA2612597C (fr) 2015-03-31
CA2612646A1 (fr) 2006-12-28
NO20080434L (no) 2008-03-17
AU2006260599A1 (en) 2006-12-28
RU2008102655A (ru) 2009-07-27
KR20080074085A (ko) 2008-08-12
EP1898945B1 (fr) 2012-12-19
EP1906994B1 (fr) 2014-04-23
CA2612646C (fr) 2015-11-24
WO2006136963A2 (fr) 2006-12-28
WO2007012976A2 (fr) 2007-02-01
US20100160218A1 (en) 2010-06-24
ZA200800255B (en) 2009-04-29
JP2008543926A (ja) 2008-12-04
JP2013151510A (ja) 2013-08-08
US20100279925A1 (en) 2010-11-04
WO2006136963A3 (fr) 2007-07-12
CN101262879A (zh) 2008-09-10
BRPI0611710A2 (pt) 2011-12-20
NO20080433L (no) 2008-03-19
EP1898945A2 (fr) 2008-03-19
CN101262880A (zh) 2008-09-10
ZA200800251B (en) 2009-04-29
RU2496515C2 (ru) 2013-10-27
DK1898945T3 (da) 2013-03-25
US20100297099A1 (en) 2010-11-25
DK1896059T3 (da) 2013-04-08
WO2006136962A2 (fr) 2006-12-28
AU2006273696A1 (en) 2007-02-01
BRPI0613137A2 (pt) 2010-12-21
RU2008102656A (ru) 2009-07-27
IL188220A0 (en) 2008-03-20
RU2496516C2 (ru) 2013-10-27
AU2006273696B2 (en) 2012-08-30
EP1896059A2 (fr) 2008-03-12
CA2612597A1 (fr) 2007-02-01
WO2006136962A3 (fr) 2007-07-12
IL188221A0 (en) 2008-03-20
DK1906994T3 (da) 2014-07-21
EP1896059B1 (fr) 2012-12-19

Similar Documents

Publication Publication Date Title
HK1137807A1 (en) Diagnosis of infections or inflammatory diseases of the airways and lungs associated with heart failure
IL193230A (en) Use of benzoxoborol derivatives in the preparation of drugs for the treatment of inflammatory diseases
EP1827555A4 (fr) Administration endoluminale d'anesthesie
IL204723A0 (en) Combination comprising purine derivatives and other compounds and the use thereof for the treatment of inflammatory and obstructive airway diseases
GB0611131D0 (en) Nicotine inhalation therapies - smoking cessation and other medical uses
EP2046430A4 (fr) Administration d'un traitement respiratoire
EP2051760A4 (fr) Administration d'un traitement respiratoire
EP2101855A4 (fr) Administration d'inhalotherapie
PL2170848T3 (pl) Pochodne pirazynonu i ich zastosowanie w leczeniu chorób płuc
EP2032156A4 (fr) Compositions et procédés pour administrer de l'oxygène
DK3542869T3 (da) Engangssøvn- og åndedrætsmonitor
EP2049054A4 (fr) Interface patient nasale et orale
IL222542A (en) Use of a compound to prepare a drug to inhibit and diagnose proteinuria in the lung
EP1744740A4 (fr) Derives d'acide phenoxyalkycarboxylique pour le traitement des maladies inflammatoires
AP2627A (en) New form of administration of racecadotril
GB2443336B (en) Spiruchostatin analogues and their medicinal use
IL194185A0 (en) Formuations of low dose diclofenac and beta-cyclodextrin
EP2086646A4 (fr) Cathéter nasal à passages d'air internes et externes
EP1982724A4 (fr) Agent therapeutique pour le traitement du syndrome metabolique et aliments contenant cet agent
PL2839836T3 (pl) Probiotyki do zastosowania przy redukowaniu objawów choroby układu oddechowego
EP1755635A4 (fr) Traitement d'affection inflammatoire des voies respiratoires
ZA200809725B (en) Preparation of antibody-or antibody-fragment-targeted immunoliposomes for systemic administration of therapeutic or diagnostic agents and uses thereof
BRPI0718388A8 (pt) etiqueta adesiva com agente amargante e agentes fluidificantes para secreções naturais das vias aéreas
EP1843781A4 (fr) Composition pour la prevention, le traitement et le diagnostic de maladies chroniques inflammatoires des voies aeriennes
HK1114567A1 (en) Airway administration of tissue factor pathway inhibitor in inflammatory conditions affecting the respiratory tract

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170623